Kairos Pharma, Ltd. (KAPA)
NYSE: KAPA · Pharmaceutical Preparations · Los Angeles, CA · filing with the SEC since 2023
Who runs Kairos Pharma, Ltd.
Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filedChief executive, as filed
Yu John S
CEO and Chairman. First filing Sep 2024, latest Nov 26, 2025, 1 filing in all.
Officers reporting now
4
of 7 people with a filing in the last fifteen months
Directors reporting now
3
8 people on the record since 2024
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Title as filed | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Bhowmick Neil | Chief Scientific Officer | Sep 2024 | Dec 30, 2025 | none |
| Yu John S | CEO and Chairman | Sep 2024 | Nov 26, 2025 | none |
| Samuelson Doug | Chief Financial Officer | Sep 2024 | Nov 26, 2025 | none |
| Murali Ramachandran | VP of Research and Development | Sep 2024 | Nov 26, 2025 | none |
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
| Name | Role | First filing | Latest filing | Sales, 12 months |
|---|---|---|---|---|
| Bae Hyun W. | director | Sep 2024 | Dec 23, 2025 | none |
| Keyoung Hansoo Michael | director | Sep 2024 | Nov 26, 2025 | none |
| Singhvi Rahul | director | Apr 2025 | Nov 26, 2025 | none |
Earlier names on the record1, newest filing first
A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.